Results 71 to 80 of about 255,779 (244)

N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1

open access: yesMolecular Cancer
Background The PD-L1/PD-1 pathway is crucial for immune regulation and has become a target in cancer immunotherapy. However, in order to improve patient selection for immune checkpoint blockade (ICB) therapies, better selection criteria are needed.
Bar Kaufman   +13 more
doaj   +1 more source

Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. [PDF]

open access: yes, 2017
Cancer-Testis antigens (CTA) are immunogenic molecules with normal tissue expression restricted to testes but with aberrant expression in up to 30% of non-small cell lung cancers (NSCLCs). Regulation of CTA expression is mediated in part through promoter
Barnett, Stephen A   +10 more
core   +2 more sources

A Modular Bioinstructive Platform Reveals Mechanistic Insights into Additive‐Free, Topography‐Driven Osteogenesis

open access: yesAdvanced Healthcare Materials, EarlyView.
Engineered microparticle topographies direct human mesenchymal stem cell osteogenesis without biochemical additives. This osteogenic commitment is driven by canonical Hedgehog signaling and followed by temporal IGF‐II engagement. Two‐photon polymerization demonstrates spatial control, enabling the engineering of topographical gradients that pattern ...
Fatmah I. Ghuloum   +5 more
wiley   +1 more source

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival : an updated analysis of KEYNOTE-010 trial

open access: yes, 2019
Background: In KEYNOTE-010, pembrolizumab versus docetaxel improved overall survival (OS) in patients with programmed death-1 protein (PD)-L1-positive advanced non-small-cell lung cancer (NSCLC).
Ahn, M-J   +20 more
core   +1 more source

IFNγ-induced PD-L1 expression is JAK2 but not JAK1 dependent and its inhibition enhances NK-cetuximab mediated ADCC of HNSCC cells [PDF]

open access: yes, 2014
Programmed death ligand 1 (PD-L1) is an immunosuppressive molecule expressed by many cancer types, including a large proportion of head and neck cancers (HNC), and ligation of its receptor, programmed death 1 (PD-1), induces exhaustion of effector T ...
Concha-Benavente, Fernando   +1 more
core   +2 more sources

Purpose‐Adaptable Reinforced 3D Hyaluronic‐Acid Based Platform to Study Pathomechanisms of the Central Nervous System

open access: yesAdvanced Healthcare Materials, EarlyView.
Platform system to create biofabricated 3D spinal cord tissue models: Combining high resolution PCL fiber placement, a customized, hyaluronic acid‐based hydrogel, two cell types (spinal cord neurons and astrocytes) together with three distinct laminin isoforms allow the formation of functional cell–cell network interactions.
Nicoletta Murenu   +12 more
wiley   +1 more source

The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance [PDF]

open access: yes, 2019
Programmed cell death protein (PD-1) and its ligands play a fundamental role in the evasion of tumor cells from antitumor immunity. Less well appreciated is the fact that the PD-1/PD-L1 axis also regulates antiviral immune responses and is therefore ...
Raftery, Martin J., Schönrich, Günther
core   +1 more source

Thermal Processing Creates Water‐Stable PEDOT:PSS Films for Bioelectronics

open access: yesAdvanced Materials, Volume 37, Issue 13, April 2, 2025.
Instead of using chemical cross–linkers, it is shown that PEDOT:PSS thin films for bioelectronics become water‐stable after a simple heat treatment. The heat treatment is compatible with a range of rigid and elastomeric substrates and films are stable in vivo for >20 days.
Siddharth Doshi   +16 more
wiley   +1 more source

The Prognostic and Therapeutic Value of PD-L1 in Glioma

open access: yesFrontiers in Pharmacology, 2019
Glioma is the most common type of primary brain tumors. After standard treatment regimen (surgical section, radiotherapy and chemotherapy), the average survival time remains merely around 14 months for glioblastoma (grade IV glioma).
Ruo Qiao Chen   +6 more
doaj   +1 more source

Alterations of immune response of non-small lung cancer with azacytidine [PDF]

open access: yes, 2013
Innovative therapies are needed for advanced Non-Small Cell Lung Cancer (NSCLC). We have undertaken a genomics based, hypothesis driving, approach to query an emerging potential that epigenetic therapy may sensitize to immune checkpoint therapy targeting
Baylin, Stephen B   +27 more
core   +1 more source

Home - About - Disclaimer - Privacy